| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2083028 | Drug Discovery Today: Therapeutic Strategies | 2007 | 7 Pages |
Abstract
Psoriasis is a common immune-mediated skin disease affecting millions of people in North America and Europe. Activated immune system, as well as the crosstalk via cytokine networks between the immune cells and epidermal keratinocytes, are involved in the pathogenesis of psoriasis. This brief review will discuss emerging therapeutic cytokine targets, ranging from advanced clinical development to early explorative research, for the treatment of psoriasis. Some of the new approaches may lead to promising new therapeutic options for psoriasis.
Section editor:Martin Braddock – Discovery BioScience, AstraZeneca R&D Charnwood, Loughborough, Leicestershire, England, UK
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Yan Zheng, Ivor Caro, Wenjun Ouyang,